Trending
- 1 GT BIOPHARMA: Announces FDA Data - GTB-3550 Trike™ Reduces Cancer Cells by 61.7% for a High-risk Myelodysplastic Syndromes (HR-MDS) Patient
- 2 UROVANT SCIENCES: Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
Newsletter
Get the latest business news and updates - delivered right to your inbox
By signing up you agree to receive email newsletters or alerts from FDA Health News. You can unsubscribe at any time.